

A Biological Basis for and Treatment of Edema Formation After Acute Brain Injury

January 7

Tuesday, 12:30 pm

Weekly Colloquium

Billings Building
Rosedale Conference Room



Speaker: Kevin Sheth, M.D.

Professor of Neurology and Neurosurgery
Associate Chair for Clinical Research,
Department of Neurology
Division Chief, Neurocritical Care and
Emergency Neurology
Director, Neuroscience ICU
Yale Medicine
New Haven, CT

Hosts: Rajiv R. Ratan, M.D., Ph.D.


For more information, please contact
Lindsey Echevarria
lechevarria@med.cornell.edu

Burke Neurological Institute

Academic Affiliate of Weill Cornell Medicine
785 Mamaroneck Avenue
White Plains, NY 10605
burke.weill.cornell.edu

Abstract

Dr. Sheth's research focuses on the identification and translation of new therapies for patients with acute neurological injury such as stroke, brain hemorrhage, and trauma. The primary goal of his group is to identify and translate innovative approaches to improved patient care, using clinical trials in neurological disease as a platform. His group has special expertise in identifying unique patient populations (large and small) using population, genomic, and other big data, collaborating with preclinical labs to prepare pharmacotherapy for translation (including drug delivery), and advancing biomarkers and outcomes that facilitate the detection of clinically relevant treatment effect. This work is aimed primarily towards patients with all forms of cerebrovascular disease including the prevention, acute treatment, and recovery of ischemic and hemorrhagic stroke.



1. Chauhan G, Adams HHH, Satizabal CL, et al. Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting [published online ahead of print, 2019 Jan 16]. *Neurology*. 2019;92(5):e486–e503. doi:10.1212/WNL.0000000000006851
2. Hanley DF, Thompson RE, Rosenblum M, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial [published correction appears in *Lancet*. 2019 Apr 20;393(10181):1596]. *Lancet*. 2019;393(10175):1021–1032. doi:10.1016/S0140-6736(19)30195-3
3. Pergakis M, Badjatia N, Chaturvedi S, et al. BIIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema. *Expert Opin Investig Drugs*. 2019;28(12):1031–1040. doi:10.1080/13543784.2019.1681967